Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

NCT05953584 is registered in ClinicalTrials.gov with Forma Therapeutics, Inc. as lead sponsor.

NCT NCT05953584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05953584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
Lead sponsor
Forma Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 20, 2023
Completion date
June 28, 2028
Enrollment
27 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease